
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026 Panel Discussion: Diversity in Clinical Trials—What’s Working, What’s Next
2
SCOPE Summit 2026 Keynote Panel: Is Radical Acceleration in Clinical Research Possible?
3
SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations
4
SCOPE Summit 2026: Reducing Patient Burden Is the Foundation of Wearable Success in Oncology
5